FI119359B - Lymfotoksiini-alfa/beta-komplekseja ja anti-lymfotoksiini-beta-reseptor ivasta-aineita kasvaintenvastaisina aineina - Google Patents
Lymfotoksiini-alfa/beta-komplekseja ja anti-lymfotoksiini-beta-reseptor ivasta-aineita kasvaintenvastaisina aineina Download PDFInfo
- Publication number
- FI119359B FI119359B FI973118A FI973118A FI119359B FI 119359 B FI119359 B FI 119359B FI 973118 A FI973118 A FI 973118A FI 973118 A FI973118 A FI 973118A FI 119359 B FI119359 B FI 119359B
- Authority
- FI
- Finland
- Prior art keywords
- ifn
- cells
- complexes
- mab
- indications
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/525—Tumour necrosis factor [TNF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US37896895A | 1995-01-26 | 1995-01-26 | |
US37896895 | 1995-01-26 | ||
US9601386 | 1996-01-26 | ||
PCT/US1996/001386 WO1996022788A1 (en) | 1995-01-26 | 1996-01-26 | LYMPHOTOXIN-α/β COMPLEXES AND ANTI-LYMPHOTOXIN-BETA RECEPTOR ANTIBODIES AS ANTI-TUMOR AGENTS |
Publications (3)
Publication Number | Publication Date |
---|---|
FI973118A0 FI973118A0 (fi) | 1997-07-25 |
FI973118A FI973118A (fi) | 1997-09-25 |
FI119359B true FI119359B (fi) | 2008-10-31 |
Family
ID=23495285
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FI973118A FI119359B (fi) | 1995-01-26 | 1997-07-25 | Lymfotoksiini-alfa/beta-komplekseja ja anti-lymfotoksiini-beta-reseptor ivasta-aineita kasvaintenvastaisina aineina |
Country Status (25)
Country | Link |
---|---|
EP (2) | EP1407781A1 (sk) |
JP (2) | JPH10513161A (sk) |
KR (2) | KR100470739B1 (sk) |
CN (3) | CN1589902A (sk) |
AT (1) | ATE268604T1 (sk) |
AU (1) | AU725351B2 (sk) |
BG (1) | BG62599B1 (sk) |
BR (1) | BR9606808A (sk) |
CA (1) | CA2211443A1 (sk) |
CZ (1) | CZ298711B6 (sk) |
DE (1) | DE69632681T2 (sk) |
DK (1) | DK0809510T3 (sk) |
EA (1) | EA000096B1 (sk) |
EE (1) | EE04453B1 (sk) |
ES (1) | ES2220972T3 (sk) |
FI (1) | FI119359B (sk) |
HK (1) | HK1006356A1 (sk) |
HU (1) | HUP9801746A3 (sk) |
NO (1) | NO322744B1 (sk) |
NZ (1) | NZ303405A (sk) |
PL (1) | PL185364B1 (sk) |
PT (1) | PT809510E (sk) |
RO (1) | RO118634B1 (sk) |
SK (1) | SK286497B6 (sk) |
WO (1) | WO1996022788A1 (sk) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5925351A (en) | 1995-07-21 | 1999-07-20 | Biogen, Inc. | Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease |
US7118742B2 (en) * | 1997-07-07 | 2006-10-10 | La Jolla Institute For Allergy And Immunology | Ligand for herpes simplex virus entry mediator and methods of use |
US6140467A (en) * | 1997-07-07 | 2000-10-31 | La Jolla Institute For Allergy And Immunology | Ligand for herpes simplex virus entry mediator and methods of use |
US7060667B1 (en) | 1998-01-30 | 2006-06-13 | Biogen Idec Ma, Inc. | Treatment of follicular lymphomas using inhibitors of the LT pathway |
DE69931944T2 (de) | 1998-10-09 | 2007-02-08 | Biogen Idec Ma Inc., Cambridge | Umkehr des viral-induzierten systemischen schocks und des atemnotsyndroms durch blockierung des lymphotoxin-beta- aktivierungsweges |
EP1326897A2 (en) * | 2000-10-13 | 2003-07-16 | Biogen, Inc. | Humanized anti-lt-beta-r antibodies |
AU2003248782A1 (en) * | 2002-07-01 | 2004-01-19 | Biogen Idec Ma Inc. | Humanized anti-lymphotoxin beta receptor antibodies |
PL377611A1 (pl) * | 2002-12-20 | 2006-02-06 | Biogen Idec Ma Inc. | Czynniki dla receptora limfotoksyny beta w połączeniu z czynnikami chemioterapeutycznymi |
EP1583503A4 (en) * | 2002-12-20 | 2006-08-09 | Biogen Idec Inc | POLYVALENT LYMPHOTOXIN BETA RECEPTOR AGONISTS AND THERAPEUTIC USE THEREOF |
JP5091476B2 (ja) | 2003-06-27 | 2012-12-05 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 均質な抗体溶液の生成のための疎水性相互作用クロマトグラフィーまたはヒンジ領域改変の使用 |
WO2005092927A1 (en) | 2004-03-23 | 2005-10-06 | Biogen Idec Ma Inc. | Receptor coupling agents and therapeutic uses thereof |
WO2006074399A2 (en) | 2005-01-05 | 2006-07-13 | Biogen Idec Ma Inc. | Multispecific binding molecules comprising connecting peptides |
EP1764371A1 (de) * | 2005-04-25 | 2007-03-21 | Xantos Biomedicine AG | Agonistische Antikörper, welche an den LT-Beta-Rezeptor binden und dadurch Adipositas assoziierte Phänotypen modulieren, und deren Verwendung in der Therapie |
CN101073665B (zh) * | 2006-05-17 | 2014-11-26 | 上海复旦张江生物医药股份有限公司 | 淋巴毒素在制备增加化疗药物敏感性的药物中的应用 |
WO2008042436A2 (en) | 2006-10-03 | 2008-04-10 | Biogen Idec Ma Inc. | Biomarkers and assays for the treatment of cancer |
US8338376B2 (en) | 2006-10-20 | 2012-12-25 | Biogen Idec Ma Inc. | Compositions comprising variant LT-B-R-IG fusion proteins |
US8067375B2 (en) | 2006-10-20 | 2011-11-29 | Biogen Idec Ma Inc. | Treatment of demyelinating disorders with soluble lymphotoxin-β-receptor |
BRPI0913687A2 (pt) * | 2008-09-30 | 2015-10-13 | Genentech Inc | marcadores biológicos preditivos da resposta da artrite reumatóide aos antagonistas da linfotoxina |
IN2014CN04961A (sk) * | 2011-12-05 | 2015-09-18 | Igenica Biotherapeutics Inc | |
IL308212A (en) | 2015-01-20 | 2024-01-01 | Igm Biosciences Inc | Tumor necrosis factor-α receptor binding molecules and their uses |
WO2022117569A1 (en) | 2020-12-02 | 2022-06-09 | Oncurious Nv | A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer |
JP2024508207A (ja) | 2020-12-02 | 2024-02-26 | ブイアイビー ブイゼットダブリュ | がんに対する組み合わせ治療におけるltbrアゴニスト |
WO2023198848A1 (en) | 2022-04-13 | 2023-10-19 | Vib Vzw | An ltbr agonist in combination therapy against cancer |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6124599A (ja) * | 1984-07-11 | 1986-02-03 | Kyowa Hakko Kogyo Co Ltd | 新規ヒトインタ−フエロン−rポリペプチド誘導体 |
JPS61277628A (ja) * | 1985-06-04 | 1986-12-08 | Asahi Chem Ind Co Ltd | 癌治療用白血球刺激材 |
US4770995A (en) * | 1985-08-29 | 1988-09-13 | New York Blood Center, Inc | Detection of the sensitivity of cells to the effects of tumor necrosis factor and lymphotoxin |
AU8228891A (en) * | 1990-06-27 | 1992-01-23 | Biogen, Inc. | Surface complexed lymphotoxin |
EP0672143B1 (en) * | 1992-12-04 | 2008-06-04 | Biogen Idec MA Inc. | Lymphotoxin-beta, lymphotoxin-beta complexes, pharmaceutical preparations and therapeutic uses thereof |
-
1996
- 1996-01-26 EE EE9700255A patent/EE04453B1/xx not_active IP Right Cessation
- 1996-01-26 JP JP8523078A patent/JPH10513161A/ja not_active Withdrawn
- 1996-01-26 CN CNA2004100070585A patent/CN1589902A/zh active Pending
- 1996-01-26 KR KR1019970705213A patent/KR100470739B1/ko not_active IP Right Cessation
- 1996-01-26 DK DK96906260T patent/DK0809510T3/da active
- 1996-01-26 RO RO97-01398A patent/RO118634B1/ro unknown
- 1996-01-26 DE DE69632681T patent/DE69632681T2/de not_active Expired - Fee Related
- 1996-01-26 KR KR10-2004-7015796A patent/KR100475492B1/ko not_active IP Right Cessation
- 1996-01-26 PT PT96906260T patent/PT809510E/pt unknown
- 1996-01-26 SK SK986-97A patent/SK286497B6/sk not_active IP Right Cessation
- 1996-01-26 CZ CZ0236197A patent/CZ298711B6/cs not_active IP Right Cessation
- 1996-01-26 NZ NZ303405A patent/NZ303405A/en not_active IP Right Cessation
- 1996-01-26 PL PL96321758A patent/PL185364B1/pl unknown
- 1996-01-26 BR BR9606808A patent/BR9606808A/pt not_active Application Discontinuation
- 1996-01-26 WO PCT/US1996/001386 patent/WO1996022788A1/en active IP Right Grant
- 1996-01-26 EA EA199700144A patent/EA000096B1/ru not_active IP Right Cessation
- 1996-01-26 AT AT96906260T patent/ATE268604T1/de not_active IP Right Cessation
- 1996-01-26 HU HU9801746A patent/HUP9801746A3/hu unknown
- 1996-01-26 CN CNB961922710A patent/CN1146442C/zh not_active Expired - Fee Related
- 1996-01-26 ES ES96906260T patent/ES2220972T3/es not_active Expired - Lifetime
- 1996-01-26 EP EP20030022584 patent/EP1407781A1/en not_active Withdrawn
- 1996-01-26 CA CA002211443A patent/CA2211443A1/en not_active Abandoned
- 1996-01-26 AU AU49704/96A patent/AU725351B2/en not_active Ceased
- 1996-01-26 EP EP96906260A patent/EP0809510B1/en not_active Expired - Lifetime
- 1996-01-26 CN CNA2006101007130A patent/CN1900116A/zh active Pending
-
1997
- 1997-07-22 NO NO19973385A patent/NO322744B1/no not_active IP Right Cessation
- 1997-07-25 FI FI973118A patent/FI119359B/fi active IP Right Grant
- 1997-08-26 BG BG101855A patent/BG62599B1/bg unknown
-
1998
- 1998-06-02 HK HK98104772A patent/HK1006356A1/xx not_active IP Right Cessation
-
2007
- 2007-03-12 JP JP2007062695A patent/JP2007169296A/ja not_active Withdrawn
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FI119359B (fi) | Lymfotoksiini-alfa/beta-komplekseja ja anti-lymfotoksiini-beta-reseptor ivasta-aineita kasvaintenvastaisina aineina | |
US7459537B2 (en) | Anti-lymphotoxin-β receptor antibodies as anti-tumor agents | |
Browning et al. | Signaling through the lymphotoxin beta receptor induces the death of some adenocarcinoma tumor lines. | |
KR101004174B1 (ko) | 세포소멸을 유도하는 시토킨 | |
US6284236B1 (en) | Cytokine that induces apoptosis | |
US20030059427A1 (en) | Isolation and characterization of highly active anti-CD40 antibody | |
CA2179196A1 (en) | Method of preventing or treating disease characterized by neoplastic cells expressing cd40 | |
US6015559A (en) | Fas antagonists | |
KR20010080073A (ko) | 림포독소 베타 경로의 차단에 의한 바이러스-유도성 전신쇼크 및 호흡 장애의 반전 | |
EP0689600B1 (en) | Process to induce the death of tumor cells | |
MXPA97005629A (en) | Linfotoxin-alpha / beta complexes and anti-tetration antibodies of lymphotoxin beta as agents anti-tu | |
Browning | Signaling through the Lymphotoxin 13 Receptor Induces the Death of Some Adenocarcinoma Tumor Lines By Jeffrey L. Browning, Konrad Miatkowski, Irene Sizing, David Griffiths, Mohammad Zafari, Christopher D. Benjamin, Werner Meier, and Fabienne Mackay |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Transfer of assignment of patent |
Owner name: BIOGEN IDEC MA INC. Free format text: BIOGEN IDEC MA INC. |
|
FG | Patent granted |
Ref document number: 119359 Country of ref document: FI |